Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10722495 | 0.97 | MGAM (0.41) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4057076 | 0.81 | — | — | |
| SCHEMBL932146 | 0.81 | — | — | |
| SCHEMBL873457 | 0.81 | GAA (0.67) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL9604212 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL7367447 | 0.79 | GAA (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4057071 | 0.79 | ALDH1A1 (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL8277426 | 0.79 | GAA (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL9547351 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL282717 | 0.79 | GAA (0.64) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| WO-2021076681-A1 | PROCESS FOR SYNTHESIS OF PICOLINAMIDES | DOW AGROSCIENCES LLC (US) | 2021-04-22 | — | — | WO | disclosed |
| EP-1931675-B1 | PYRAZOLO(1, 5A) PYRIMIDINES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8232393-B2 | Aromatic AZA heterocycles, method of production and use of the material in organic electronics | OSRAM OPTO SEMICONDUCTORS GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232393-B2 | Aromatic AZA heterocycles, method of production and use of the material in organic electronics | OSRAM OPTO SEMICONDUCTORS GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-7595368-B2 | Nanofilm compositions with polymeric components | COVALENT PARTNERS, LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070276145-A1 | Method of Preparing a Ring Compound Having Two Adjacent Chiral Centers | ICOS CORPORATION (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070276145-A1 | Method of Preparing a Ring Compound Having Two Adjacent Chiral Centers | ICOS CORPORATION (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070082902-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082902-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| EP-0279366-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-08-12 | — | — | EP | disclosed |
| US-4960887-A | REACTING PROPANEDIIMIDATE WITH CARBONIC ACID IMINEDERIVATIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
| EP-0279366-A2 | Process for the preparation of pyrimidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MGAM 2375/4885GAA 999/4885SI 968/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | MGAM 2375/4885GAA 999/4885SI 968/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | MGAM 2375/4885GAA 999/4885SI 968/4885 |
| US-20070276145-A1 | Method of Preparing a Ring Compound Having Two Adjacent Chiral Centers | NISCH, NDC1, SUCLG2 | MGAM 3029/4885GAA 1861/4885SI 456/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | MGAM 1475/4885GAA 2478/4885SI 1919/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | MGAM 2375/4885GAA 999/4885SI 968/4885 |
| US-20070082902-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CHEK1, CHEK2, BUB1 | MGAM 4629/4885GAA 2665/4885SI 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.